Contact: Laura Gerding
University of Missouri School of Medicine
Caption: With a new $3.4 million grant from the National Institutes of Health, scientist Stefan Sarafianos, Ph.D., MU Chancellor's Chair for Excellence in Molecular Virology, is developing new compounds that target an enzyme in HIV that has escaped the reach of existing drugs.
Credit: University of Missouri School of Medicine
Usage Restrictions: None
Related news release: Researchers attack HIV's final defenses before drug-resistant mutations emerge